Taipei, Taiwan

Wei-Han Lee

This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Obi Pharma Inc.. Active years: 2023-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei-Han Lee. Retrieved from https://idiyas.com/inventor/wei-han-lee-551vwwix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovator in Cancer Treatment: The Contributions of Wei-Han Lee

Introduction

Wei-Han Lee, an accomplished inventor based in Taipei, Taiwan, has made significant contributions in the field of cancer treatment through his innovative approaches in vaccine development. With a total of three patents to his name, he continues to push the boundaries of medical science.

Latest Patents

Wei-Han Lee's most recent patents encapsulate groundbreaking innovations in the realm of carbohydrate vaccines aimed at inducing immune responses against cancer. One notable patent focuses on therapeutic compositions that include Globo H-KLH conjugates and therapeutic antibodies. This invention provides methods for making and using these compositions to treat proliferative diseases, notably cancer. It emphasizes the role of these therapeutic conjugates, which link an antigen to a carrier, enhancing the body’s immune response to detect and combat abnormal cells.

Another significant patent introduces vaccines that feature a higher density of carbohydrate antigens. This innovation involves the conjugation of these antigens to a diphtheria toxin (DT) as a carrier protein, with an impressive ratio of carbohydrate antigen to carrier protein exceeding 5:1. Additionally, this patent presents a novel saponin adjuvant that is intended to inhibit cancer cells through effective vaccine administration.

Career Highlights

Wei-Han Lee's career is highlighted by his dedication to improving health outcomes through innovative research. His work at Obi Pharma Inc. positions him at the forefront of biotechnology, enabling him to translate his ideas into practical solutions that have the potential to save lives. His advancements in vaccine technology represent a critical step forward in tackling cancer and enhancing patients' immune responses.

Collaborations

Collaboration has been a crucial element in Wei-Han Lee's journey. He has worked alongside esteemed colleagues such as Cheng-Der Tony Yu and I-Ju Chen, enhancing the research environment and facilitating the sharing of knowledge in pursuit of innovative solutions for cancer treatment. These collaborations help foster a sense of community and joint effort in addressing significant medical challenges.

Conclusion

In conclusion, Wei-Han Lee's contributions to the development of cancer vaccines underscore the importance of innovation in the medical field. His patents not only pave the way for new cancer treatments but also emphasize the collaborative nature required in scientific advancements. As Wei-Han Lee continues his work at Obi Pharma Inc., his inventions will likely play a pivotal role in reshaping the approaches to cancer therapy and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…